TRIO is pleased to share the news that the US FDA, based on the results from the NATALEE (TRIO033) trial, has approved ribociclib in combination with an aromatase inhibitor to reduce the risk of recurrence in patients with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease. This approval broadens the population eligible for targeted therapies to help reduce the risk of their cancer coming back. Thank you to the TRIO team for your engagement; you can be proud of this achievement. Thank you to Novartis for this successful collaboration and for putting their trust in TRIO to conduct this practice-changing trial. Thank you to our investigators and partners for your key contribution to making this possible. Catherine Marle CEO TRIO
TRIO - Translational Research in Oncology
Research Services
Edmonton, Alberta 13,328 followers
Advancing cancer research. Life-changing results.
About us
TRIO is a unique, full-service oncology clinical research organization (CRO) that leverages the strengths of our worldwide network of Investigators, academic leaders, patient advocates and our clinical research team to accelerate drug development. We’ve spent decades conducting oncology trials from inception to completion, focusing on the best research and science to guide the development of innovative and biologically sound therapies. This translational research model allows us to bring targeted concepts into clinics on the most rational development path. We find the shortest course to save lives. We are focused. We care. We deliver.
- Website
-
http://www.trioncology.org
External link for TRIO - Translational Research in Oncology
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- Edmonton, Alberta
- Type
- Nonprofit
- Founded
- 1997
- Specialties
- Translational Research, Oncology, and Clinical Trials (Phase I, II and III)
Locations
-
Primary
Suite 1100
9925-109 Street
Edmonton, Alberta T5K 2J8, CA
-
Biopark
11, rue Watt
Paris, 75013, FR
-
1248 Office 360
WTC 3
Montevideo, 11300, UY
Employees at TRIO - Translational Research in Oncology
-
Hélène BOUSSEMART-MANSOURI
Global Manager, Trial Operations Optimization at TRIO - Translational Research in Oncology
-
Barb Blundon, CPA, CMA
Excellent seasoned accounting and business professional looking to make a difference in your company
-
Barb Gaudreault, PMP
Information Services Project Manager at TRIO - Translational Research in Oncology
-
Ionut Temciuc
Senior Study Manager at TRIO - Translational Research in Oncology
Updates
-
📅 Today (September 16) at #ESMO24, Dr. Peter Fasching, member of our Board and Breast Cancer Scientific Committee, presented the latest data from the NATALEE (TRIO033) trial. Ribociclib combined with endocrine therapy shows a deepening iDFS benefit beyond the three-year treatment period. The results indicate a 28.5% reduced risk of recurrence (HR=0.715; CI 95% 0.609–0.840; P<0.0001) compared to ET alone in patients with stage II and III HR+/HER2- early breast cancer (EBC). These long-term results highlight the efficacy of ribociclib in reducing the risk of recurrence in a broad population of EBC patients, and underscore TRIO's role in collaborating with Novartis in this pivotal trial. Together, we are redefining treatment standards and bringing new hope to patients at significant risk of recurrence despite adjuvant endocrine therapy.
-
A big thank you to everyone who joined us at the TRIO Reception during #ESMO24! It was a pleasure to connect with our incredible investigators, colleagues and valued stakeholders. Your presence made the evening truly special, and we’re excited to continue our work together in advancing cancer research. #OncologyCollaboration
-
Today at #ESMO24, Gottfried E Konecny presented the results from the first-in-human phase I study of TORL-1-23, an antibody-drug conjugate targeting the oncofetal protein Claudin-6 (CLDN6). The study demonstrated that TORL-1-23 is well tolerated and has promising antitumor activity in heavily pretreated patients with CLDN6-expressing ovarian cancer. We are excited to collaborate with TORL Biotherapeutics, LLC to bring new options for patients with gynecological cancers!
-
On September 14 at #ESMO24, Jonathan W. Goldman presented a trials in progress poster about the First in Human study of TORL-4-500 in patients with advanced cancer. TORL-4-500, is an anti-DLK1 (Delta like non-canonical Notch ligand 1) ADC that has shown selective pre-clinical efficacy and is now being investigated in this phase 1 trial. Discover how we are advancing cancer treatment with groundbreaking therapies. 🧬 #CancerResearch #OncologyInnovation #TRIOatESMO
-
Have you visited the TRIO booth 444 at #ESMO2024? Stop by and say hello to our TRIO ambassador Ashpreet Singh in Hall 3.
-
We’ve arrived in Barcelona and are ready to kick off #ESMO24! Our team is thrilled to be here and eager to dive into the latest developments in oncology. Let’s connect, collaborate and drive the future of cancer care together.
-
From this Friday, stop by and meet our TRIO ambassador, Ashpreet Singh, and the TRIO team at booth 444 in Hall 3 during #ESMO24! We’re excited to share TRIO’s latest updates with you. See you there!
-
Barcelona, here we come! TRIO is excited to be part of the European Society for Medical Oncology (ESMO) Congress, where the brightest minds in oncology gather. TRIO team members Catherine Marle, Valerie Bee-Munteanu, Matthieu Rupin and Rodrigo Fresco will be attending. Meet them in person in Barcelona! #ESMO24